Expression And Clinical Significance Of Transketolase Like 1(TKTL1) In Prostate Cancer

Objective: Prostate cancer is one of the most common tumors in elderly male patients,and its incidence is increasing in recent years.In American,the incidence rate for male patients is the highest.Therefore,the early screening,early diagnosis,and early treatment are the most effective methods for preventing prostate cancer.Nowadays,the main methods for early screening of prostate cancer include digital rectal inspection(DRE),prostate specific antigen(PSA)test,MR of prostate,and so on.Those promote the early diagnosis rate of prostate cancer.However,the rate of missed diagnosis of prostate cancer is still very high,and we need to find more indicators with higher specificity and sensitivity.To assist the diagnosis of prostate cancer and evaluate the degree of malignancy.A large number of literatures have demonstrated that transketolase like protein 1(TKTL1)is abnormally expressed in a large number of cancers,including urothelial carcinoma.In this paper,the expression of TKTL1 in prostate cancer was examined by immunohistochemical method,and the relationship between expression of TKTL1 and the prognosis in prostate cancer was analyzed.Methods: Streptavidin-peroxidase(SP)was used to detect the expression of TKTL1 in prostate cancer tissues and normal tissues.The chi-square test was used to study the relationship between the expression of TKTL1 and various clinicopathological factors,and the Kaplan-meier survival curve was used to analyze the prognosis of prostate cancer,and log-rank test was performed for the results.Results:1.The positive rate of TKTL1 in Benign Prostatic Hyperplasia(BPH)was22.7%(5/22),and the positive rate in prostate cancer tissues was 55%(55/100).The expression of TKTL1 in prostate cancer tissues was significantly higher than that in BPH(P=0.006).2.In prostate cancer,the positive rate of TKTL1 was 64.9%(37/57)in patients with lymph node metastasis,and 41.9%(18/43)in patients without lymph node metastasis.The expression of TKTL1 in patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis(P=0.022).3.In prostate cancer tissues,the positive rate of TKTL1 was 68.9%(31/45)in patients with bone metastasis,and 49.1%(27/55)in patients without bone metastasis.The expressionof TKTL1 in patients with bone metastasis was significantly higher than that in patients without bone metastasis(P=0.046).4.In prostate cancer tissues,the positive rate of TKTL1 was 65.1%(28/43)in patients older than 70 years old,and 52.6%(30/57)in patients younger than or equal to 70 years old.There was no significant difference in TKTL1 between patients older than or equal to 70 years old and patients younger than or equal to 70 years old(P=0.21).5.In prostate cancer tissues,the positive rate of TKTL1 was 46.5%(20/43)in low-risk and medium-risk patients,and 66.7%(38/57)in high-risk patients.The expression of TKTL1 in high-risk patients was significantly higher than that in low-risk and medium-risk groups(P=0.043).6.Among the patients after radical prostatectomy,the biochemical recurrence survival time of patients with positive TKTL1 was(41.1±3.9)months,and that of patients with negative TKTL1 was(53.6 ± 3.3)months,and the difference was statistically significant(P=0.027).7.Among the prostate cancer patients receiving endocrine therapy,the time of castrated resistance in patients with positive TKTL1 was(18.0±2.9)months,and that in patients with negative TKTL1 was(32.2±5.4)months,with statistically significant difference(P=0.014).Conclusion: TKTL1 is highly expressed in prostate cancer tissues,significantly higher than that in prostate hyperplasia tissues.The expression of TKTL1 in prostate cancer patients was related to lymph node metastasis,bone metastasis and risk grade of patients,regardless of age.In patients receiving radical prostatectomy,the expression of TKTL1 is associated with postoperative biochemical recurrence.TKTL1 expression is associated with castration resistance in prostate cancer patients undergoing endocrine therapy.TKTL1 may have great significance for the diagnosis,treatment and prognosis of prostate cancer,and may become a biomarker for the diagnosis and prognosis of prostate cancer.